Russell J. Hamilton

The University of Arizona, Tucson, Arizona, United States

Are you Russell J. Hamilton?

Claim your profile

Publications (47)149.63 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: To evaluate the variations in dwell times and doses expected when using an episcleral brachytherapy device for treatment of neovascular agerelated macular degeneration (n-AMD) based on accurate imaging modalities Data from 40 eyes from 40 subjects with known n- AMD acquired through the Distance of Choroid Study (DOCS) conducted at Moorfields Eye Hospital was used to determine the target depth; the distance from the outer scleral surface of the eye, through the choroid, to the apex of the choroidal neovascularization (CNV). Each subject underwent, in triplicate, enhanced-depth Spectral Domain Optical Coherence Tomography (SD-OCT), Swept Source Optical Coherence Tomography, (SS-OCT) and Ocular Ultrasound (O-US). These data are the most comprehensive and accurate measurements of the dimensions of the CNV and adjacent layers of the eye for this cohort of patients. During treatment of n-AMD, patients receive a dose of 24Gy to the apex at the target depth. Using the percentage depth dose for a Sr-90 episcleral brachytherapy device, dwell times and doses to the apex were computed to determine the expected variations. The mean target depth and the 95% confidence interval (CI) determined by combining O-US with SD-OCT were 1326 (956,1696)µm and with SS-OCT were 1332 (970,1693)µm. The calculated corresponding mean dwell times and 95% (CI) were 334 (223,445)s and 335 (226,445)s for SD-OCT and SS-OCT determined depths, respectively. The corresponding mean apex dose and 95% (CI) were 24 (35.9,18.0)Gy (SD-OCT) and 24 (35.6,18.1)Gy (SS-OCT). For episcleral brachytherapy treatment of n-AMD, using a patient population average target depth for treatment planning is inadequate, resulting in dose variations of a factor of approximately two over the 95% CI and larger variations for a nontrivial segment of the population. Each patient should have individualized imaging studies to determine the target depth for use in the dwell time calculation. Study was sponsored by Salutaris Medical Devices, Ltd., a subsidiary of Salutaris Medical Devices, Inc. Hamilton and Marsteller are founders of Salutaris Medical Devices, Inc. Drew, McGovern and Vitali are minor equity holders in Salutaris Medical Devices, Inc.
    Medical Physics 06/2015; 42(6):3334. DOI:10.1118/1.4924377 · 3.01 Impact Factor
  • Brachytherapy 03/2014; 13:S101. DOI:10.1016/j.brachy.2014.02.384 · 1.99 Impact Factor
  • International Journal of Radiation OncologyBiologyPhysics 11/2012; 84(3):S625. DOI:10.1016/j.ijrobp.2012.07.1669 · 4.18 Impact Factor
  • R Hamilton · T Cetas · J Gordon · W Lutz · L Marsteller
    [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: Describe the dosimetry of an episcleral brachytherapy device. Methods: The SMD-I device is designed to treat exudative age-related macular degeneration (AMD) and employs a Sr-90/Y-90 source encapsulated in a stainless steel cylinder. The source is welded to a flexible wire allowing it to travel from a shielded vault in the SMD-I handle to the distal end of a curved cannula to deliver a therapeutic dose of radiation through the sclera to the neovascular target in the subchoroidal space. The SMD-I handle and vault are comprised of Ultem, a lightweight radiation tolerant plastic, which shields the surgeon. Dose calculations were performed using the MCNPX radiation transport code. The absolute dose rate was determined using radiochromic film (GAFChromatic© MD-55) at a point in solid water 2.0mm from the source center perpendicular to the cannula. Dose rates at several depths were measured using Kodak EDR2 film in water equivalent phantoms to compare with the absolute dose rate measurement and MCNPX calculations. The surgeon's hand dose received while manipulating the device with the source in the vault was measured using standard TL (thermoluminescence) finger ring dosimeters, TL ChipstratesTM, and calculated with MCNPX. Results: The absolute dose rate 2.0mm from the source center is 0.45 Gy/min/mCi. The EDR2 film results agree with the absolute dose measurement and the MCNPX calculations. The dose rate decreases rapidly with depth so that the dose at the target depth (3mm) is approximately 8 times less than at 1mm depth (sclera). The dose distribution is sensitive to the angle between the cannula and the neovascular plane. Both TL methods yield a maximum dose rate of 6 μSv/min mCi to the surgeon's fingers consistent with the MCNPX calculation. Conclusions: The SMD-I device permits accurate delivery of a therapeutic radiation dose for the treatment of exudative AMD. Russell J. Hamilton is a founder and currently serves on the Scientific Advisory Board of Salutaris Medical Devices, Inc. Wendell Lutz and Thomas Cetas serve on the Scientific Advisory Board of Salutaris Medical Devices, Inc. All authors have received financial support from Salutaris Medical Devices, Inc.
    Medical Physics 06/2012; 39(6):3774. DOI:10.1118/1.4735394 · 3.01 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: High energy X-rays have been used for cancer therapy since their discovery in 1895. Major radiobiological discoveries and technological advances in radiation physics have greatly increased the accuracy of radiation. The recent integration of radiation therapy and imaging systems provides radiation oncologists with sophisticated dose delivery capability allowing continued improvements in the control of loco-regional and metastatic disease while decreasing toxicity. Key technical aspects of current radiation therapy are described with examples extending to several clinical areas.
    Journal of Surgical Oncology 05/2011; 103(6):627-38. DOI:10.1002/jso.21837 · 2.84 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Prostate cancer is a major reason for death of men in the world. A very effective method which is increasingly being used for treatment of this cancer is brachytherapy. For being most effective and having less side effects a good treatment planning is needed for choosing the source plant positions and in case of HDR brachytherapy for choosing the dwelling times. In the recent Treatment Planning (TP) commercial packages, the boundaries of prostate and its adjacent critical organs are defined by the physicist and the dwelling position is calculated by such methods as simulated annealing. In the TP method investigated in this research, a program is developed that uses patient CT DICOM file to model the exact phantom for MCNP5 calculations. Choosing the source seeds positions, the isodose surfaces and the dose gained by other critical organs as well as the whole body could be calculated accurately as the modeled phantom is the closest simulation to the patients’ specific anatomy. The result of the MCNP5 calculations is used to train an artificial neural network (ANN), with the DICOM data and the source seeds positions as input and the dose distributions as the output. Using this ANN an optimization is performed to find the best source positions that satisfy the TG-43 protocol. The main advantage of this method is its accuracy and speed in calculations which gives the opportunity to correct the plan as the seeds placement is deviated from the pre operation planned position through the planting process.
    Joint International Conference on Supercomputing in Nuclear Applications and Monte Carlo 2010 (SNA + MC2010), Hitotsubashi Memorial Hall, Tokyo, Japan; 10/2010
  • Qianyi Xu · Zhijun He · Jiajin Fan · Russell J Hamilton · Yan Chen · C-M Ma · Lei Xing
    [Show abstract] [Hide abstract]
    ABSTRACT: Current gated radiation therapy starts with simulation 4DCT images of a patient with lung cancer. We propose a method to confirm the phase of 4DCT for planning and setup position at the time of treatment. An intensity-based rigid algorithm was developed in this work to register an orthogonal set of on-board projection X-ray images with each phase of the 4DCT. Multiple DRRs for one of ten 4DCT phases are first generated and the correlation coefficient (CC) between the projection X-ray image and each DRR is computed. The maximum value of CC for the phase is found via a simulated annealing optimization process. The whole process repeats for all ten phases. The 4DCT phase that has the highest CC is identified as the breathing phase of the X-ray. The phase verification process is validated by a moving phantom study. Thus, the method may be used to independently confirm the correspondence between the gating phase at the times of 4DCT simulation and radiotherapy delivery. When the intended X-ray phase and actual gating phase are consistent, the registration of the DRRs and the projection images may also yield the values of patient shifts for treatment setup. This method could serve as the 4D analog of the conventional setup film as it provides both verification of the specific phase at the time of treatment and isocenter positioning shifts for treatment delivery.
    Physica Medica 10/2009; 26(3):117-25. DOI:10.1016/j.ejmp.2009.09.001 · 1.85 Impact Factor
  • K Hadad · B Ganapol · RJ Hamilton · CJ Watchman · Y Xu
    American Nuclear Society Annual MeetingAmerican Nuclear Society Annual Meeting; 01/2009
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Respiratory gating and tumor tracking for dynamic multileaf collimator delivery require accurate and real-time localization of the lung tumor position during treatment. Deriving tumor position from external surrogates such as abdominal surface motion may have large uncertainties due to the intra- and interfraction variations of the correlation between the external surrogates and internal tumor motion. Implanted fiducial markers can be used to track tumors fluoroscopically in real time with sufficient accuracy. However, it may not be a practical procedure when implanting fiducials bronchoscopically. In this work, a method is presented to track the lung tumor mass or relevant anatomic features projected in fluoroscopic images without implanted fiducial markers based on an optical flow algorithm. The algorithm generates the centroid position of the tracked target and ignores shape changes of the tumor mass shadow. The tracking starts with a segmented tumor projection in an initial image frame. Then, the optical flow between this and all incoming frames acquired during treatment delivery is computed as initial estimations of tumor centroid displacements. The tumor contour in the initial frame is transferred to the incoming frames based on the average of the motion vectors, and its positions in the incoming frames are determined by fine-tuning the contour positions using a template matching algorithm with a small search range. The tracking results were validated by comparing with clinician determined contours on each frame. The position difference in 95% of the frames was found to be less than 1.4 pixels (approximately 0.7 mm) in the best case and 2.8 pixels (approximately 1.4 mm) in the worst case for the five patients studied.
    Medical Physics 01/2009; 35(12):5351-9. DOI:10.1118/1.3002323 · 3.01 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To evaluate the effectiveness of implanted gold marker registration compared with bony fusion alignment for patient positioning using the Novalis Body system. Eighteen treatment fractions of stereotactic spinal radiotherapy were analyzed for three patients who each had three implanted gold seeds placed near their spinal lesions before radiotherapy. At each treatment session, the registration was first performed using bony fusion and then verified by another bony fusion, followed by registration with implanted markers. The software reported the calculated shifts for both methods. In addition, the actual three-dimensional coordinate positions of the markers were read using PTDReader software. Implanted marker positions were analyzed for variations in individual maker coordinate displacement, interseed distances, and area transcribed by them. Measured positional differences between the two fusion methods were applied to actual treatment plans to assess the resulting dosimetric differences in the treatment plans. Both fusion algorithms were shown to localize the patient well, within 1.5 mm, but the implanted marker fusion consistently related less deviation from the planned isocenter, by approximately 0.5 mm, than did the bony fusion. Exceptions to this localization occurred when the average interseed distances were less than 3.0 cm and resulted in the two registration methods being equivalent. Implanted spine markers were also shown to have less than 0.7 mm deviation from the planned marker coordinates, indicating no migration of the seeds. Dose distributions were found to be highly dependant on differences in fusion method, with spinal cord doses up to 350% greater with bony fusion than with implanted markers. Implanted markers used with the Novalis Body system have been shown to be more effective in patient positioning than the bony fusion method in the thoracic spine.
    Neurosurgery 06/2008; 62(5 Suppl):A62-8; discussion A68. DOI:10.1227/01.neu.0000325938.08605.eb · 3.03 Impact Factor
  • C. J. Watchman · R. J. Hamilton
    International Journal of Radiation OncologyBiologyPhysics 11/2007; 69(3). DOI:10.1016/j.ijrobp.2007.07.2293 · 4.18 Impact Factor
  • Source
    Qianyi Xu · Russell J Hamilton · Robert A Schowengerdt · Steve B Jiang
    [Show abstract] [Hide abstract]
    ABSTRACT: A dynamic multi-leaf collimator (DMLC) can be used to track a moving target during radiotherapy. One of the major benefits for DMLC tumor tracking is that, in addition to the compensation for tumor translational motion, DMLC can also change the aperture shape to conform to a deforming tumor projection in the beam's eye view. This paper presents a method that can track a deforming lung tumor in fluoroscopic video using active shape models (ASM) (Cootes et al 1995 Comput. Vis. Image Underst. 61 38-59). The method was evaluated by comparing tracking results against tumor projection contours manually edited by an expert observer. The evaluation shows the feasibility of using this method for precise tracking of lung tumors with deformation, which is important for DMLC-based real-time tumor tracking.
    Physics in Medicine and Biology 10/2007; 52(17):5277-93. DOI:10.1088/0031-9155/52/17/012 · 2.92 Impact Factor
  • Qianyi Xu · Russell J Hamilton
    [Show abstract] [Hide abstract]
    ABSTRACT: This paper proposes a novel respiratory detection method based on diaphragm motion measurements using a 2D ultrasound unit. The proposed method extracts a respiratory signal from an automated analysis of the internal diaphragm motion during breathing. The respiratory signal may be used for gating. Ultrasound studies of diaphragm breathing motion were performed on four volunteers. The ultrasound video stream was captured and transferred to a personal computer and decomposed into individual image frames. After straightforward image analysis, region of interest selection, and filtering, the mutual information (MI) and correlation coefficients (CCs) between a selected reference frame and all other frames were computed. The resulting MI and CC values were discovered to produce a signal corresponding to the respiratory cycle in both phase and magnitude. We also studied the diaphragm motion of two volunteers during repeated deep inspiration breath holds (DIBH) and found a slight relaxation motion of the diaphragm during the DIBH, suggesting that the residual motion may be important for treatments delivered at this breathing phase. Applying the proposed respiratory detection method to these ultrasound studies, we found that the MI and CC values demonstrate the relaxation behavior, indicatingthat our method may be used to determine the radiation triggering time for a DIBH technique.
    Medical Physics 05/2006; 33(4):916-21. DOI:10.1118/1.2178451 · 3.01 Impact Factor
  • Andy Su · Michael J Blend · Danny Spelbring · Russell J Hamilton · Ashesh B Jani
    [Show abstract] [Hide abstract]
    ABSTRACT: The purpose of this study was to analyze regions of uptake in normal structures on postprostatectomy radioimmunoscintigraphy (RIS) images by evaluating differences in the overlap volumes of prostate fossa clinical target volume (CTV) and planning target volume (PTV) using correlative computed tomography (CT) images. The electronic records of 13 patients who received external beam radiotherapy postprostatectomy and who underwent a vessel-based RIS/CT registration were reviewed. For each patient, the RIS-defined CTV (CTV(RIS)) was compared (in terms of the overlap volume with the surrounding bladder, rectum, pubic symphysis, and penile bulb) with the CT-defined CTV(pre) before this registration and also with CTV(post) (the final target volume used for treatment). Similar analyses were done for PTV(RIS), PTV(pre), and PTV(post) defined in each case to be the corresponding CTV + 1-cm margin. CTV(RIS) overlapped significantly more with the bladder, rectum, and symphysis, but not with the penile bulb, than did either the CTV(pre) or CTV(post). However, the corresponding PTV analyses revealed no significant differences between any of the overlap volumes of any of the PTVs with the bladder, rectum, and penile bulb, but did reveal a significant difference between the PTV(RIS) and PTV(post) overlap volumes with the symphysis compared with PTV(pre) overlap volumes with the symphysis. On RIS images, there appear to be areas of uptake in the bladder, rectum, and pubic symphysis but not the penile bulb; however, the dosimetric consequences of this uptake for radiation treatment planning are minimal on the bladder, rectum, and penile bulb, but require segmentation for dose reduction to the pubic symphysis.
    Clinical Nuclear Medicine 04/2006; 31(3):139-44. DOI:10.1097/01.rlu.0000200461.93250.a5 · 2.86 Impact Factor
  • A. C. Turner · C. J. Watchman · R. J. Hamilton
    48th Annual Meeting of the; 01/2006
  • A. B. Jani · A. Su · M. J. Blend · D. Spelbring · R. J. Hamilton
    International Journal of Radiation OncologyBiologyPhysics 10/2005; 63. DOI:10.1016/j.ijrobp.2005.07.869 · 4.18 Impact Factor
  • Source
    Benjamin Armbruster · Russell J Hamilton · Arthur K Kuehl
    [Show abstract] [Hide abstract]
    ABSTRACT: There are three ways to determine the spectrum of a clinical photon beam: direct measurement, modelling the source and reconstruction from ion-chamber measurements. We focus on reconstruction because the necessary equipment is readily available and it provides independent confirmation of source models for a given machine. Reconstruction methods involve measuring the dose in an ion chamber after the beam passes through an attenuator. We gain information about the spectrum from measurements using attenuators of differing compositions and thicknesses since materials have energy dependent attenuation. Unlike the procedures used in other papers, we do not discretize or parametrize the spectrum. With either of these two approximations, reconstruction is a least squares problem. The forward problem of going from a spectrum to a series of dose measurements is a linear operator, with the composition and thickness of the attenuators as parameters. Hence the singular value decomposition (SVD) characterizes this operator. The right singular vectors form a basis for the spectrum, and, at first approximation, only those corresponding to singular values above a threshold are measurable. A more rigorous error analysis shows with what confidence different components of the spectrum can be measured. We illustrate this theory with simulations and an example utilizing six sets of dose measurements with water and lead as attenuators.
    Physics in Medicine and Biology 12/2004; 49(22):5087-99. DOI:10.1088/0031-9155/49/22/005 · 2.92 Impact Factor
  • D. Levin · RJ Hamilton
    International Journal of Radiation OncologyBiologyPhysics 09/2004; 60(1). DOI:10.1016/j.ijrobp.2004.07.203 · 4.18 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Our goal was to evaluate the role of radioimmunoscintigraphy (RIS) directed against prostate-specific membrane antigen (PSMA) in influencing postprostatectomy radiotherapy (RT) toxicity and biochemical control. The records of 107 postprostatectomy RT patients were reviewed. The group for whom no RIS scan was obtained (group A, n = 54) was identified as was the group for whom a RIS scan was obtained (group B, n = 53). Group B was further subdivided into those who had a RIS and CT-scan correlation to aid in treatment planning (subgroup B1, n = 40) versus those who did not (subgroup B2, n = 13). Gastrointestinal (GI) and genitourinary (GU) toxicities were reviewed for each of these groups and subgroups and compared. Biochemical failures (defined as 2 successive PSA rises after a nadir of >or=0.2 ng/mL) were identified to generate biochemical failure-free survival (BFFS) curves for each of the groups and subgroups. No significant differences in late toxicity were observed between any group or subgroup. However, acute GI toxicity was higher in group B versus group A (P = 0.026), and acute GU toxicity was higher in subgroup B2 versus subgroup B1 (P = 0.050). Overall, most toxicity was grade 1 or 2; only one case of grade 3 toxicity and no cases of grade 4 or 5 toxicity were observed. Three-year BFFS was higher for group B versus group A (80.7% vs. 75.5%) and for subgroup B1 versus subgroup B2 (84.5% vs. 71.6%). On multivariate analysis of pretreatment (age, race), surgical/staging (stage, grade, margin status, extracapsular extension, lymph node status, seminal vesicle invasion, post-radical retropubic prostatectomy [RRP] prostate-specific antigen [PSA] nadir, maximum post-RRP PSA, and RRP-to-RT interval), and treatment (hormone therapy, RT dose, RT technique, RIS scan, and RIS/CT correlation) factors on BFFS, the only covariate reaching significance was RIS/CT correlation (P = 0.042). A small BFFS advantage was observed in patients for whom RIS was used to guide RT decision making and treatment planning; however, this advantage only reached significance in this study for those for whom the RIS/CT correlation was used to guide target definition. The improved PSA control using RIS was achieved with a small increase in acute toxicity but with no observed change in late toxicity. These findings can serve as the basis for prospective studies in this area of investigation.
    Journal of Nuclear Medicine 08/2004; 45(8):1315-22. · 5.56 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to evaluate the role of radioimmunoscintigraphy (RIS) directed against prostate-specific membrane antigen (PSMA) in influencing postradical retropubic prostatectomy (RRP) radiotherapy (RT) decision making. The records of consecutive patients who underwent RRP, who were referred for consideration of RT, and for whom an RIS scan was obtained were reviewed. The RT decisions, with regard to (a) the decision to offer RT and (b) the general volume to be treated [prostate fossa (PF) only versus PF + pelvis (P)] before knowledge of the RIS findings were charted. The RIS findings, with regard to uptake in the PF, uptake in the P, or extrapelvic (EP) uptake were tabulated. Then, the RT treatment decisions based on the RIS knowledge were evaluated and compared with the pre-RIS RT treatment decisions. Of the 54 patients originally referred for post-RRP RT, the initial decision was to recommend RT to the PF only in 52 cases and to PF+P in 2 cases. The RIS findings were as follows: PF only, 43 patients; PF+P, 8 patients; PF+EP, 2 patients; PF+P+EP, 1 patient. After knowledge of these RIS results, the decision to offer RT was withdrawn in 4 of 54 patients (7.4%; P = 0.046). Furthermore, RIS changed the general treatment volume (PF only to PF+P) in 6 of 54 patients (11.1%; P = 0.015). In total, RIS altered the RT decision in 10 of 54 patients (18.5%; P = 0.0067). Three-year biochemical failure-free survival (with failure defined as 2 consecutive prostate-specific antigen [PSA] rises above 0.2 ng/mL after PSA nadir) was 78%; no patient, disease, or treatment factor reached statistical significance on univariate or multivariate analysis. RIS was found to influence post-RRP RT decision making for the identification of patients not likely to benefit from RT and for guiding general target volume definition.
    Journal of Nuclear Medicine 05/2004; 45(4):571-8. · 5.56 Impact Factor

Publication Stats

618 Citations
149.63 Total Impact Points


  • 2004–2012
    • The University of Arizona
      • Department of Radiation Oncology
      Tucson, Arizona, United States
    • University of Illinois at Chicago
      Chicago, Illinois, United States
  • 1996–1998
    • University of Chicago
      • • Department of Radiation & Cellular Oncology
      • • Department of Radiology
      Chicago, IL, United States
    • Cook County Hospital
      • Division of Urology
      Chicago, Illinois, United States